Overview:

Summary

Global Markets Direct’s, 'Thyroid Gland Disorders - Pipeline Review, Q2 2011', provides an overview of the Thyroid Gland Disorders therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Gland Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Gland Disorders. 'Thyroid Gland Disorders - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thyroid Gland Disorders.
- A review of the Thyroid Gland Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thyroid Gland Disorders pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Thyroid Gland Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Thyroid Gland Disorders pipeline depth and focus of Thyroid Gland Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Thyroid Gland Disorders Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Thyroid Gland Disorders 6
Thyroid Gland Disorders Therapeutics under Investigation by Universities/Institutes 8
Late Stage Products 9
Comparative Analysis 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Thyroid Gland Disorders Therapeutics - Products under Investigation by Universities/Institutes 11
Thyroid Gland Disorders - Therapeutics Assessment 12
Assessment by Monotherapy Products 12
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Late Stage Drug Profiles 17
Levothyroxine Sodium - Drug Profile 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Thyrotropin Releasing Hormone - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Thyroxine - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Thyroid Gland Disorders - Featured News 20
May 06, 2010: Cytochroma Reports Positive Phase I Results For CTAP201 Injection In Hemodialysis Patients 20
Mar 10, 2010: Lithera Completes Phase I Clinical Trial Of LIPO-102 20
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 23
Contact Us 23
Disclaimer 23"

List of Tables
Number of Products Under Development for Thyroid Gland Disorders, Q2 2011 6
Products under Development for Thyroid Gland Disorders – Comparative Analysis, Q2 2011 7
Number of Products under Investigation by Universities/Institutes, Q2 2011 8
Comparative Analysis by Late Stage Development, Q2 2011 9
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 10
Products under Investigation by Universities/Institutes, Q2 2011 11
Assessment by Monotherapy Products, Q2 2011 12
Assessment by Stage and Route of Administration, Q2 2011 14
Assessment by Molecule Type, Q2 2011 16"

List of Figures
Number of Products under Development for Thyroid Gland Disorders, Q2 2011 6
Products under Development for Thyroid Gland Disorders – Comparative Analysis, Q2 2011 7
Products under Investigation by  Universities/Institutes, Q2 2011 8
Late Stage Products, Q2 2011 9
Mid Clinical Stage Products, Q2 2011 10
Assessment by Monotherapy Products, Q2 2011 12
Assessment by Route of Administration, Q2 2011 13
Assessment by Stage and Route of Administration, Q2 2011 14
Assessment by Molecule Type, Q2 2011 15
Assessment by Stage and Molecule Type, Q2 2011 16